ERBB2 and neoplasm: Given the fact that MD.45 cells expressing this construct were also active in vivo by inhibiting the growth of HER-2/neu+ tumour cells (see below), it becomes evident that our HER/ζ construct offers a novel and promising tool for future therapeutic interventions in cancer.